Exeter – Confidence in Concept 2019
Lead Research Organisation:
UNIVERSITY OF EXETER
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The Confidence in Concept (CIC) scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions to flexibly support a portfolio of early stage translational research projects. CIC is designed to accelerate the transition from discovery research to viable translational projects by supporting preliminary studies to establish proof-of-concept so that the approach will then become competitive for more substantial translational funding.
Organisations
- UNIVERSITY OF EXETER (Lead Research Organisation)
- AstraZeneca (Collaboration)
- Defence Science & Technology Laboratory (DSTL) (Collaboration)
- Max Planck Society (Collaboration)
- Singer Instruments (Collaboration)
- Murdoch University (Collaboration)
- University of the West of England (Collaboration)
- Environment Agency (Collaboration)
- Medicines Discovery Catapult (Collaboration)
- Senisca Ltd (Collaboration)
- University of Laval (Collaboration)
People |
ORCID iD |
Neil Andrew Robert Gow (Principal Investigator) |
Publications
Fletcher J
(2024)
The Citizen Phage Library: Rapid Isolation of Phages for the Treatment of Antibiotic Resistant Infections in the UK
in Microorganisms
Harries LW
(2023)
Dysregulated RNA processing and metabolism: a new hallmark of ageing and provocation for cellular senescence.
in The FEBS journal
Lee BP
(2021)
Senotherapeutic Drugs: A New Avenue for Skincare?
in Plastic and reconstructive surgery
Luckett AM
(2023)
Utility of genetic risk scores in type 1 diabetes.
in Diabetologia
Paull GC
(2024)
Beyond compliance: harmonising research and husbandry practices to improve experimental reproducibility using fish models.
in Biological reviews of the Cambridge Philosophical Society
Winter MJ
(2022)
A Combined Human in Silico and CRISPR/Cas9-Mediated in Vivo Zebrafish Based Approach to Provide Phenotypic Data for Supporting Early Target Validation.
in Frontiers in pharmacology
Description | A roadmap towards commercialisation of novel senotherapeutic technologies. |
Geographic Reach | National |
Policy Influence Type | Contribution to new or improved professional practice |
Description | Launching the Citizen Phage Library as a national resource for adjunctive phage therapy. |
Geographic Reach | National |
Policy Influence Type | Contribution to new or improved professional practice |
Impact | Provided evidence to the House of Commons Science and Technology committee regarding clinical use of bacteriophages. |
Description | Launching the Citizen Phage Library as a national resource for adjunctive phage therapy. |
Geographic Reach | National |
Policy Influence Type | Contribution to new or improved professional practice |
Impact | Working with four UK hospitals to provide phages for patients and engaging with the MHRA to identify a route to use in the UK. |
Description | A preclinical drug screening platform for treatment-resistant depression |
Amount | £546,792 (GBP) |
Funding ID | MRC-MR/028972/1 |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 12/2022 |
End | 12/2024 |
Description | Establishing the roles of oestrogen receptor 1 (ESR1) in olfactory development and function using novel CRISPR/Cas9-based knockouts in the zebrafish. |
Amount | £540,000 (GBP) |
Funding ID | BB/Y00003X/1 |
Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
Sector | Public |
Country | United Kingdom |
Start |
Description | Innovate UK ICURe Follow on funding for A roadmap towards commercialisation of novel senotherapeutic technologies project |
Amount | £240,000 (GBP) |
Organisation | Innovate UK |
Sector | Public |
Country | United Kingdom |
Start | 03/2021 |
Description | Launching the Citizen Phage Library as a national resource for adjunctive phage therapy. |
Amount | £50,000 (GBP) |
Organisation | Royal Devon and Exeter Hospital |
Sector | Hospitals |
Country | United Kingdom |
Start |
Description | MRC Impact Accelerator Account - The Pharma Pollution Hub: a national think tank leading action to reduce the environmental impact of medicines used in UK healthcare |
Amount | £38,273 (GBP) |
Funding ID | MR/X502820/1 |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 11/2023 |
End | 12/2024 |
Description | The zebrafish - a fast and reliable vertebrate model to study gene function to support target validation in the search for new human drug therapies. |
Amount | £600,000 (GBP) |
Organisation | AstraZeneca |
Sector | Private |
Country | United Kingdom |
Start |
Title | A preclinical drug screening platform for treatment-resistant depression |
Description | Establishment of a novel animal model for depression using a highly specific early life stress exposure in zebrafish |
Type Of Material | Biological samples |
Year Produced | 2021 |
Provided To Others? | No |
Impact | Establishment of a novel animal model for depression using a highly specific early life stress exposure in zebrafish |
Title | Launching the Citizen Phage Library as a national resource for adjunctive phage therapy |
Description | We have developed improved methods to identify synergisms and antagonisms between phages and antibiotics during adjunctive therapies. Our new method captures both early-infection (chemical synergy) and late-infection (suppression of resistance) interactions. We have also developed methods to use kymographs and timelapse plaque assays to evaluate whether phages should be given to patients in combination or sequentially to maximise killing potential. |
Type Of Material | Antibody |
Year Produced | 2021 |
Provided To Others? | No |
Impact | We have developed improved methods to identify synergisms and antagonisms between phages and antibiotics during adjunctive therapies. Our new method captures both early-infection (chemical synergy) and late-infection (suppression of resistance) interactions. We have also developed methods to use kymographs and timelapse plaque assays to evaluate whether phages should be given to patients in combination or sequentially to maximise killing potential. |
Title | The zebrafish - a fast and reliable vertebrate model to study gene function to support target validation in the search for new human drug therapies. |
Description | We have established stable transgenic zebrafish lines in which Cas9 protein expression is induced by chemical (doxycycline) exposure and the induction can be tracked by GFP fluorescence. Also, we have developed transgenic approach to express guide RNA (gRNA) specifically in the heart using zebrafish cmlc2 promoter and ribozyme RNA modification system. These tools will promote precise control of genome editing in heart tissue. |
Type Of Material | Physiological assessment or outcome measure |
Year Produced | 2023 |
Provided To Others? | No |
Impact | We have established stable transgenic zebrafish lines in which Cas9 protein expression is induced by chemical (doxycycline) exposure and the induction can be tracked by GFP fluorescence. Also, we have developed transgenic approach to express guide RNA (gRNA) specifically in the heart using zebrafish cmlc2 promoter and ribozyme RNA modification system. These tools will promote precise control of genome editing in heart tissue. |
Title | The zebrafish - a fast and reliable vertebrate model to study gene function to support target validation in the search for new human drug therapies. |
Description | We have preliminary data generated supporting the usefulness of our system in spatiotemporal control of gene knock-out in zebrafish. Based on these encouraging data, we will further test and refine the system to make it applicable for AstraZeneca in target gene validation. |
Type Of Material | Biological samples |
Year Produced | 2021 |
Provided To Others? | No |
Impact | We have preliminary data generated supporting the usefulness of our system in spatiotemporal control of gene knock-out in zebrafish. Based on these encouraging data, we will further test and refine the system to make it applicable for AstraZeneca in target gene validation. |
Title | Launching the Citizen Phage Library as a national resource for adjunctive phage therapy |
Description | From 137 Citizen Science samples we have isolated just over 200 new phages, of which ~90% have potential clinical use in phage therapy against three of the top six greatest threats of AMR globally. Genome analyses, host ranges etc will be made publically available shortly upon submission of the manuscripts being prepared. |
Type Of Material | Data analysis technique |
Year Produced | 2022 |
Provided To Others? | Yes |
Impact | From 137 Citizen Science samples we have isolated just over 200 new phages, of which ~90% have potential clinical use in phage therapy against three of the top six greatest threats of AMR globally. Genome analyses, host ranges etc will be made publically available shortly upon submission of the manuscripts being prepared. |
Title | Launching the Citizen Phage Library as a national resource for adjunctive phage therapy. |
Description | Our phage library has now reached >800 phages. |
Type Of Material | Database/Collection of data |
Year Produced | 2023 |
Provided To Others? | No |
Impact | Our phage library has now reached >800 phages. |
Description | A preclinical drug screening platform for treatment-resistant depression |
Organisation | Max Planck Society |
Department | Max Planck Institute of Psychiatry |
Country | Germany |
Sector | Academic/University |
PI Contribution | Collaboration was established with the Translational Research in Psychiatry group of Professor Elisabeth Binder, MD. PhD. Director of Max Planck Institute of Psychiatry in Munich, Germany. The goal is to determine whether the biomarkers that we had identified in our treatment-resistance depression zebrafish model are also found in human organoid system. |
Collaborator Contribution | Collaboration was established with the Translational Research in Psychiatry group of Professor Elisabeth Binder, MD. PhD. Director of Max Planck Institute of Psychiatry in Munich, Germany. The goal is to determine whether the biomarkers that we had identified in our treatment-resistance depression zebrafish model are also found in human organoid system. |
Impact | Collaboration was established with the Translational Research in Psychiatry group of Professor Elisabeth Binder, MD. PhD. Director of Max Planck Institute of Psychiatry in Munich, Germany. The goal is to determine whether the biomarkers that we had identified in our treatment-resistance depression zebrafish model are also found in human organoid system. |
Start Year | 2021 |
Description | A roadmap towards commercialisation of novel senotherapeutic technologies. |
Organisation | Medicines Discovery Catapult |
Country | United Kingdom |
Sector | Private |
PI Contribution | Both the above funders contributed financially along with SENISCA. Contributions from all parties = £265,000 ENISCA successfully engaged with the Medicines Discovery Catapult, who provided us with a roadmap around the emerging regulatory landscape for oligonucleotide biologics. We also used this funding to engage Yello Studios to provide us with marketing materials (pitch deck and website) which were key to our successful equity fundraising. Collaboration with Murdoch University (Perth, Aus), where SENISCA has an embedded member of staff and member of our Scientific Advisory Board. We are also in the final stages of negotiation towards signing our first commercial co-development deal with a large US-based cosmetics corporate for our skin aesthetics arm. |
Collaborator Contribution | Both the above funders contributed financially along with SENISCA. Contributions from all parties = £265,000 ENISCA successfully engaged with the Medicines Discovery Catapult, who provided us with a roadmap around the emerging regulatory landscape for oligonucleotide biologics. We also used this funding to engage Yello Studios to provide us with marketing materials (pitch deck and website) which were key to our successful equity fundraising. Collaboration with Murdoch University (Perth, Aus), where SENISCA has an embedded member of staff and member of our Scientific Advisory Board. We are also in the final stages of negotiation towards signing our first commercial co-development deal with a large US-based cosmetics corporate for our skin aesthetics arm. |
Impact | Both the above funders contributed financially along with SENISCA. Contributions from all parties = £265,000 ENISCA successfully engaged with the Medicines Discovery Catapult, who provided us with a roadmap around the emerging regulatory landscape for oligonucleotide biologics. We also used this funding to engage Yello Studios to provide us with marketing materials (pitch deck and website) which were key to our successful equity fundraising. Collaboration with Murdoch University (Perth, Aus), where SENISCA has an embedded member of staff and member of our Scientific Advisory Board. We are also in the final stages of negotiation towards signing our first commercial co-development deal with a large US-based cosmetics corporate for our skin aesthetics arm. |
Start Year | 2021 |
Description | A roadmap towards commercialisation of novel senotherapeutic technologies. |
Organisation | Murdoch University |
Country | Australia |
Sector | Academic/University |
PI Contribution | Both the above funders contributed financially along with SENISCA. Contributions from all parties = £265,000 ENISCA successfully engaged with the Medicines Discovery Catapult, who provided us with a roadmap around the emerging regulatory landscape for oligonucleotide biologics. We also used this funding to engage Yello Studios to provide us with marketing materials (pitch deck and website) which were key to our successful equity fundraising. Collaboration with Murdoch University (Perth, Aus), where SENISCA has an embedded member of staff and member of our Scientific Advisory Board. We are also in the final stages of negotiation towards signing our first commercial co-development deal with a large US-based cosmetics corporate for our skin aesthetics arm. |
Collaborator Contribution | Both the above funders contributed financially along with SENISCA. Contributions from all parties = £265,000 ENISCA successfully engaged with the Medicines Discovery Catapult, who provided us with a roadmap around the emerging regulatory landscape for oligonucleotide biologics. We also used this funding to engage Yello Studios to provide us with marketing materials (pitch deck and website) which were key to our successful equity fundraising. Collaboration with Murdoch University (Perth, Aus), where SENISCA has an embedded member of staff and member of our Scientific Advisory Board. We are also in the final stages of negotiation towards signing our first commercial co-development deal with a large US-based cosmetics corporate for our skin aesthetics arm. |
Impact | Both the above funders contributed financially along with SENISCA. Contributions from all parties = £265,000 ENISCA successfully engaged with the Medicines Discovery Catapult, who provided us with a roadmap around the emerging regulatory landscape for oligonucleotide biologics. We also used this funding to engage Yello Studios to provide us with marketing materials (pitch deck and website) which were key to our successful equity fundraising. Collaboration with Murdoch University (Perth, Aus), where SENISCA has an embedded member of staff and member of our Scientific Advisory Board. We are also in the final stages of negotiation towards signing our first commercial co-development deal with a large US-based cosmetics corporate for our skin aesthetics arm. |
Start Year | 2021 |
Description | A roadmap towards commercialisation of novel senotherapeutic technologies. |
Organisation | Senisca Ltd |
Country | United Kingdom |
Sector | Private |
PI Contribution | We have discovered a new molecular mechanism by which cells become senescent, which can be targeted for reversal of senescence and rejuvenation of cell function. Furthermore, we have identified several points of intervention, and obtained proof of principle data from several disease-relevant human cell types that senescence can be reversed. Our data show that this approach is feasible and can form the basis for a new generation of treatments for age-related disease |
Collaborator Contribution | Our Associates Paul Edwards and Kirsty Semple of SENISCA will provide their time (£500/day) as in-kind contribution (~£10,000). KS and PE are two experienced start up consultants with commercial and medicinal chemistry experience to aid with development of pre- and post-incorporation materials as well as investment marketing materials that will be presented to investors at suitable events throughout the rest of 2020/21. |
Impact | Suuceesful application for £39,575.00 MRC Confidence in concept |
Start Year | 2020 |
Description | Collaborations on Compassionate Phage Therapy |
Organisation | University of Laval |
Country | Canada |
Sector | Academic/University |
PI Contribution | Copies of our library now also shared with Université Laval to support Canadian efforts for compassionate phage therapy. MTAs also in place with Berkeley and Singapore General Hospitals. |
Collaborator Contribution | Host materials - signed MTA |
Impact | None to date |
Start Year | 2024 |
Description | Launching the Citizen Phage Library as a national resource for adjunctive phage therapy. |
Organisation | Defence Science & Technology Laboratory (DSTL) |
Country | United Kingdom |
Sector | Public |
PI Contribution | Collaborating with DSTL to develop phage therapeutics for Coxiella. Collaborating with Singer Instruments to develop optimised plaque picking with machine learning to improve selection of plaques for downstream processing. Collaborating with the Environment Agency to screen national wastewater samples for potential therapeutic phages. Partnership with Dann Turner at UWE to work on Acietobacter baumannii phages. |
Collaborator Contribution | Collaborating with DSTL to develop phage therapeutics for Coxiella. Collaborating with Singer Instruments to develop optimised plaque picking with machine learning to improve selection of plaques for downstream processing. Collaborating with the Environment Agency to screen national wastewater samples for potential therapeutic phages. Partnership with Dann Turner at UWE to work on Acietobacter baumannii phages. |
Impact | Collaborating with DSTL to develop phage therapeutics for Coxiella. Collaborating with Singer Instruments to develop optimised plaque picking with machine learning to improve selection of plaques for downstream processing. Collaborating with the Environment Agency to screen national wastewater samples for potential therapeutic phages. Partnership with Dann Turner at UWE to work on Acietobacter baumannii phages. |
Start Year | 2021 |
Description | Launching the Citizen Phage Library as a national resource for adjunctive phage therapy. |
Organisation | Environment Agency |
Country | United Kingdom |
Sector | Public |
PI Contribution | Collaborating with DSTL to develop phage therapeutics for Coxiella. Collaborating with Singer Instruments to develop optimised plaque picking with machine learning to improve selection of plaques for downstream processing. Collaborating with the Environment Agency to screen national wastewater samples for potential therapeutic phages. Partnership with Dann Turner at UWE to work on Acietobacter baumannii phages. |
Collaborator Contribution | Collaborating with DSTL to develop phage therapeutics for Coxiella. Collaborating with Singer Instruments to develop optimised plaque picking with machine learning to improve selection of plaques for downstream processing. Collaborating with the Environment Agency to screen national wastewater samples for potential therapeutic phages. Partnership with Dann Turner at UWE to work on Acietobacter baumannii phages. |
Impact | Collaborating with DSTL to develop phage therapeutics for Coxiella. Collaborating with Singer Instruments to develop optimised plaque picking with machine learning to improve selection of plaques for downstream processing. Collaborating with the Environment Agency to screen national wastewater samples for potential therapeutic phages. Partnership with Dann Turner at UWE to work on Acietobacter baumannii phages. |
Start Year | 2021 |
Description | Launching the Citizen Phage Library as a national resource for adjunctive phage therapy. |
Organisation | Singer Instruments |
Country | United Kingdom |
Sector | Private |
PI Contribution | Collaborating with DSTL to develop phage therapeutics for Coxiella. Collaborating with Singer Instruments to develop optimised plaque picking with machine learning to improve selection of plaques for downstream processing. Collaborating with the Environment Agency to screen national wastewater samples for potential therapeutic phages. Partnership with Dann Turner at UWE to work on Acietobacter baumannii phages. |
Collaborator Contribution | Collaborating with DSTL to develop phage therapeutics for Coxiella. Collaborating with Singer Instruments to develop optimised plaque picking with machine learning to improve selection of plaques for downstream processing. Collaborating with the Environment Agency to screen national wastewater samples for potential therapeutic phages. Partnership with Dann Turner at UWE to work on Acietobacter baumannii phages. |
Impact | Collaborating with DSTL to develop phage therapeutics for Coxiella. Collaborating with Singer Instruments to develop optimised plaque picking with machine learning to improve selection of plaques for downstream processing. Collaborating with the Environment Agency to screen national wastewater samples for potential therapeutic phages. Partnership with Dann Turner at UWE to work on Acietobacter baumannii phages. |
Start Year | 2021 |
Description | Launching the Citizen Phage Library as a national resource for adjunctive phage therapy. |
Organisation | University of the West of England |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Collaborating with DSTL to develop phage therapeutics for Coxiella. Collaborating with Singer Instruments to develop optimised plaque picking with machine learning to improve selection of plaques for downstream processing. Collaborating with the Environment Agency to screen national wastewater samples for potential therapeutic phages. Partnership with Dann Turner at UWE to work on Acietobacter baumannii phages. |
Collaborator Contribution | Collaborating with DSTL to develop phage therapeutics for Coxiella. Collaborating with Singer Instruments to develop optimised plaque picking with machine learning to improve selection of plaques for downstream processing. Collaborating with the Environment Agency to screen national wastewater samples for potential therapeutic phages. Partnership with Dann Turner at UWE to work on Acietobacter baumannii phages. |
Impact | Collaborating with DSTL to develop phage therapeutics for Coxiella. Collaborating with Singer Instruments to develop optimised plaque picking with machine learning to improve selection of plaques for downstream processing. Collaborating with the Environment Agency to screen national wastewater samples for potential therapeutic phages. Partnership with Dann Turner at UWE to work on Acietobacter baumannii phages. |
Start Year | 2021 |
Description | The zebrafish - a fast and reliable vertebrate model to study gene function to support target validation in the search for new human drug therapies. |
Organisation | AstraZeneca |
Country | United Kingdom |
Sector | Private |
PI Contribution | Parnership with AstraZeneca is growing and an UKRI funding was granted for the genome editing project (see Further Funding section). We also had one-day in-person meeting with AstaraZeneca drug discovery team in Exeter in October 2022 to discuss further collaboration. BSRC Indutrial Partnership Award (BBSRC-IPA) was awarded to the collaboration project with AstraZeneca "Establishing precise genome editing in zebrafish and its application to advance understanding of the Wnt/PCP signalling pathway" (PI: Steffen Scholpp, CoI: Charles Tyler, RcoI: Yosuke Ono). In the 3-years project, we will apply an advanced CRISPR/Cas9-based genome editing technology in zebrafish model. £600,000 was funded by BBSRC and AstraZeneca. |
Collaborator Contribution | Parnership with AstraZeneca is growing and an UKRI funding was granted for the genome editing project (see Further Funding section). We also had one-day in-person meeting with AstaraZeneca drug discovery team in Exeter in October 2022 to discuss further collaboration. BSRC Indutrial Partnership Award (BBSRC-IPA) was awarded to the collaboration project with AstraZeneca "Establishing precise genome editing in zebrafish and its application to advance understanding of the Wnt/PCP signalling pathway" (PI: Steffen Scholpp, CoI: Charles Tyler, RcoI: Yosuke Ono). In the 3-years project, we will apply an advanced CRISPR/Cas9-based genome editing technology in zebrafish model. £600,000 was funded by BBSRC and AstraZeneca. |
Impact | Parnership with AstraZeneca is growing and an UKRI funding was granted for the genome editing project (see Further Funding section). We also had one-day in-person meeting with AstaraZeneca drug discovery team in Exeter in October 2022 to discuss further collaboration. BSRC Indutrial Partnership Award (BBSRC-IPA) was awarded to the collaboration project with AstraZeneca "Establishing precise genome editing in zebrafish and its application to advance understanding of the Wnt/PCP signalling pathway" (PI: Steffen Scholpp, CoI: Charles Tyler, RcoI: Yosuke Ono). In the 3-years project, we will apply an advanced CRISPR/Cas9-based genome editing technology in zebrafish model. £600,000 was funded by BBSRC and AstraZeneca. |
Start Year | 2021 |
Title | A roadmap towards commercialisation of novel senotherapeutic technologies. |
Description | Background patent now transferred to SENISCA Ltd following reaching assignment trigger of £2m capital raised. |
IP Reference | |
Protection | Patent / Patent application |
Year Protection Granted | 2023 |
Licensed | Yes |
Impact | Background patent now transferred to SENISCA Ltd following reaching assignment trigger of £2m capital raised. |
Title | Launching the Citizen Phage Library as a national resource for adjunctive phage therapy. |
Description | We have now supplied phages to four countries for compassionate use. |
Type | Preventative Intervention - Physical/Biological risk modification |
Current Stage Of Development | Small-scale adoption |
Year Development Stage Completed | 2023 |
Development Status | Under active development/distribution |
Impact | We have now supplied phages to four countries for compassionate use. |
Title | Treatment of 10 year old with cystic fibrosis/Pseudomonas aeruginosa. |
Description | We were asked through PhageDirectory to supply phages that could treat a 10 year old cystic fibrosis patient in Switzerland with a pan-resistant strain of Pseudomonas aeruginosa. Within three days of receiving the strain we had identified three phages that were clinically suitable from our citizen science samples. These phages have since been screened and trained to reduce emergence of resistance in the patient. Phages will be shipped to Switzerland in April to begin treatment in May. |
Type | Therapeutic Intervention - Vaccines |
Year Development Stage Completed | 2021 |
Development Status | Closed |
Impact | We were asked through PhageDirectory to supply phages that could treat a 10 year old cystic fibrosis patient in Switzerland with a pan-resistant strain of Pseudomonas aeruginosa. Within three days of receiving the strain we had identified three phages that were clinically suitable from our citizen science samples. These phages have since been screened and trained to reduce emergence of resistance in the patient. Phages will be shipped to Switzerland in April to begin treatment in May. |
Title | Open-source infrastructure for hosting a Citizen Phage Library portal website |
Description | Open-source infrastructure for hosting a Citizen Phage Library portal website that captures metadata from samples. |
Type Of Technology | New/Improved Technique/Technology |
Year Produced | 2021 |
Impact | Open-source infrastructure for hosting a Citizen Phage Library portal website that captures metadata from samples. |
Company Name | Senisca |
Description | Senisca develops technology that aims to reverse cellular senescence. |
Year Established | 2020 |
Impact | SENISCA Ltd. Spun out from University of Exeter in Oct 20. Currently at 10x FTE positions in UK with a further 0.5x FTE position embedded in labs at Murdoch University. |
Website | https://www.senisca.com/ |
Description | Article in The Biologist re Launching the Citizen Phage Library as a national resource for adjunctive phage therapy project |
Form Of Engagement Activity | A magazine, newsletter or online publication |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Media (as a channel to the public) |
Results and Impact | wrote an article in The Biologist, which gained significant readership and led to recruitment of phage hunters from across the globe. (https://thebiologist.rsb.org.uk/biologist-features/hunting-for-holes-of-hope) |
Year(s) Of Engagement Activity | 2021 |
Description | Collaboration Meeting with Industrial Partners. |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Industry/Business |
Results and Impact | Workshop with partners to discuss next steps of the continued collaboration/partnership with Astrazenica on the project 'The zebrafish - a fast and reliable vertebrate model to study gene function to support target validation in the search for new human drug therapies' |
Year(s) Of Engagement Activity | 2024 |
Description | Contribution to 'The Good Virus' by Tom Ireland |
Form Of Engagement Activity | A magazine, newsletter or online publication |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Public/other audiences |
Results and Impact | Contribution to 'The Good Virus' by Tom Ireland |
Year(s) Of Engagement Activity | 2024 |
URL | https://www.waterstones.com/book/the-good-virus/tom-ireland/9781529365245 |
Description | Established the citizenphage portal (https://citizenphage.com) re Launching the Citizen Phage Library as a national resource for adjunctive phage therapy project |
Form Of Engagement Activity | Engagement focused website, blog or social media channel |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | Established the citizenphage portal (https://citizenphage.com) to recruit citizen scientists. |
Year(s) Of Engagement Activity | 2021 |
Description | Launching the Citizen Phage Library as a national resource for adjunctive phage therapy. |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Schools |
Results and Impact | Completed two outreach events at schools, one public outreach event on water quality, and a public outreach event at Torbay Museum. |
Year(s) Of Engagement Activity | 2023 |
Description | Live chat for Performed a livestreamed "Fireside Chat" on World Phage Day re Launching the Citizen Phage Library as a national resource for adjunctive phage therapy |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Media (as a channel to the public) |
Results and Impact | Performed a livestreamed "Fireside Chat" on World Phage Day to discuss the Citizen Phage Library project through the Exeter Science Centre facebook page |
Year(s) Of Engagement Activity | 2021 |
Description | Media interview for New Scientist re Launching the Citizen Phage Library as a national resource for adjunctive phage therapy |
Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Media (as a channel to the public) |
Results and Impact | Was approached for comment by reporter for New Scientist on phage therapy, following a discussion on our work https://institutions.newscientist.com/article/2304997-phage-therapies-for-superbug-infections-are-being-tested-in-belgium/ |
Year(s) Of Engagement Activity | 2021 |
Description | National and international presentations at all major diabetes meetings - Developing a 'from blood' T1D-GRS biochip |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | Developing a 'from blood' T1D-GRS biochip - National and international presentations at all major diabetes meetings - |
Year(s) Of Engagement Activity | 2023,2024 |
Description | Outreach event - Sidmouth Science Festival 2021 re Launching the Citizen Phage Library as a national resource for adjunctive phage therapy. |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Public/other audiences |
Results and Impact | Outreach event at Sidmouth Science Festival in 2021 to discuss AMR with the general public. |
Year(s) Of Engagement Activity | 2021 |
Description | Transdisciplinary colloquium on psychedelics at Exeter re Detecting identity shifts in addiction treatment with KARE therapy project |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Other audiences |
Results and Impact | Set up transdisciplinary colloqiuim on psychedelics at Exeter |
Year(s) Of Engagement Activity | 2021 |
Description | Visited four primary and secondary schools in the SouthWest re Launching the Citizen Phage Library as a national resource for adjunctive phage therapy project |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Schools |
Results and Impact | Visited four primary and secondary schools in the SouthWest to talk about phage therapy and AMR with Years 10-11 pupils (>150 pupils total) re Launching the Citizen Phage Library as a national resource for adjunctive phage therapy project. |
Year(s) Of Engagement Activity | 2021 |